Cancer News and Research

Latest Cancer News and Research

Testicular cancer survivors at risk of effective treatment

Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.

20 Oct 2009

Seguro Surgical obtains global marketing rights to use a novel abdominal surgery device

Seguro Surgical, Inc., a medical device development company specializing in the commercialization of surgical instrumentation, today announced that it has acquired, from The Johns Hopkins University, the global marketing rights to a novel device for use in abdominal surgery.

20 Oct 2009

Highly educated women deal less well with psychological aspects of breast cancer

Well-educated women and those who live alone are emotionally the hardest hit by breast cancer, according to the findings of a new Australian study announced during October's Breast Cancer Awareness Month.

20 Oct 2009

Tempur-Pedic Hugs Back campaign to help fund research for pancreatic cancer

Tempur-Pedic International Inc. (NYSE: TPX), the leading manufacturer, marketer and distributor of premium mattresses and pillows worldwide, today announces the Tempur-Pedic Hugs Back campaign, featuring a limited edition version of the company's popular My Tempur-Pedic Teddy Bear®.

20 Oct 2009

Physicians say thyroid surgery safe for older people

Thyroid surgery is safe for older patients, say physicians who found only slight differences in rates of complications and hospital readmissions in a multi-year study.

20 Oct 2009

Age, gender and malignancies pose significant risk factors for TIVADs survival

It is common practice to insert totally implantable venous access devices (TIVADs) in cancer patients beginning a course of chemotherapy to eliminate potential peripheral venous access problems; however, risk factors impacting the survival of TIVADs remain unclear.

20 Oct 2009

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.

20 Oct 2009

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.

20 Oct 2009

The Affordable Nutrition Index helps people to find budget-friendly nutritious foods

A new food rating system that analyzes both nutrition and cost value of food may now make it easier for people to find budget-friendly, nutritious foods in today-s tough economy.

20 Oct 2009

Right combination of estrogen and SERM can reduce breast cancer risk

The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk, Yale researchers report in an abstract presented at the American Society for Reproductive Medicine (ASRM) scientific meeting in Atlanta, Georgia, October 17-21.

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

Phase Forward's DefineValidator tool available for CDISC adopters

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced the release of its DefineValidator tool, Release 1.0, as a free download for CDISC adopters.

20 Oct 2009

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.

20 Oct 2009

UT student receives fellowship grant for pre-eclampsia research

Roxanna Irani, a M.D./Ph.D. student at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS), has received a $10,000 fellowship for her efforts to better understand a condition known as pre-eclampsia that threatens the lives of expectant women and their unborn children.

20 Oct 2009

Health Canada issues Notice of Non-Compliance to Winston Laboratories for CIVANEX

Winston Laboratories, Inc. (“Winston Labs”), a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced that it has received a Notice of Non-compliance (“NON”) from the Therapeutics Drug Directorate, Health Canada (the “Directorate”) for its New Drug Submission (NDS) for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.

20 Oct 2009

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

20 Oct 2009

FDA approves new oral medication for renal cell carcinoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.

20 Oct 2009

Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

20 Oct 2009

Antioxidant extracts of G.biloba leaves may protect cells from radiation damage

Antioxidant extracts of the leaves of the Gingko biloba tree may protect cells from radiation damage, according to a study published in the International Journal of Low Radiation. The discovery may one day be used to help reduce side effects in cancer patients undergoing radiotherapy.

20 Oct 2009

Article evaluating StemEx therapy for leukemia and lymphoma to be published

Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.

19 Oct 2009

Cancer News and Research

Latest Cancer News and Research

Testicular cancer survivors at risk of effective treatment

Seguro Surgical obtains global marketing rights to use a novel abdominal surgery device

Highly educated women deal less well with psychological aspects of breast cancer

Tempur-Pedic Hugs Back campaign to help fund research for pancreatic cancer

Physicians say thyroid surgery safe for older people

Age, gender and malignancies pose significant risk factors for TIVADs survival

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

The Affordable Nutrition Index helps people to find budget-friendly nutritious foods

Right combination of estrogen and SERM can reduce breast cancer risk

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Phase Forward's DefineValidator tool available for CDISC adopters

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

UT student receives fellowship grant for pre-eclampsia research

Health Canada issues Notice of Non-Compliance to Winston Laboratories for CIVANEX

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

FDA approves new oral medication for renal cell carcinoma

Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia

Antioxidant extracts of G.biloba leaves may protect cells from radiation damage

Article evaluating StemEx therapy for leukemia and lymphoma to be published

Understanding the DNA Damage Response in Innate Immunity eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in